Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT - Get Free Report) had its price objective raised by equities researchers at Morgan Stanley from $26.00 to $27.00 in a report issued on Monday, Benzinga reports. The firm currently has an "equal weight" rating on the biotechnology company's stock. Morgan Stanley's price objective would suggest a potential downside of 22.41% from the stock's previous close.
A number of other equities analysts also recently commented on LKFT. Raymond James Financial reaffirmed a "market perform" rating on shares of Lakefront Biotherapeutics American Depositary Shares in a report on Thursday. UBS Group upgraded shares of Lakefront Biotherapeutics American Depositary Shares to a "buy" rating in a research note on Wednesday, September 23rd. Weiss Ratings raised shares of Lakefront Biotherapeutics American Depositary Shares from a "hold (c-)" rating to a "hold (c)" rating in a report on Friday, October 2nd. Royal Bank Of Canada upgraded shares of Lakefront Biotherapeutics American Depositary Shares from a "sector perform" rating to an "outperform" rating and raised their price target for the stock from $26.00 to $45.00 in a research report on Wednesday, September 23rd. Finally, TD Cowen assumed coverage on Lakefront Biotherapeutics American Depositary Shares in a research note on Friday. They issued a "strong-buy" rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $36.00.
View Our Latest Stock Report on Lakefront Biotherapeutics American Depositary Shares
Lakefront Biotherapeutics American Depositary Shares Stock Up 2.4%
NASDAQ:LKFT traded up $0.82 during trading hours on Monday, reaching $34.80. 80,646 shares of the stock were exchanged, compared to its average volume of 199,750. The firm has a 50 day simple moving average of $30.36 and a 200-day simple moving average of $29.94. Lakefront Biotherapeutics American Depositary Shares has a 52 week low of $25.68 and a 52 week high of $36.24. The stock has a market capitalization of $2.29 billion, a P/E ratio of -24.68 and a beta of 0.22.
Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT - Get Free Report) last issued its quarterly earnings results on Wednesday, November 11th. The biotechnology company reported ($0.05) earnings per share for the quarter. The firm had revenue of $7.87 million during the quarter. As a group, analysts expect that Lakefront Biotherapeutics American Depositary Shares will post -1.46 earnings per share for the current year.
Hedge Funds Weigh In On Lakefront Biotherapeutics American Depositary Shares
A number of institutional investors and hedge funds have recently added to or reduced their stakes in LKFT. Commonwealth Equity Services LLC bought a new stake in Lakefront Biotherapeutics American Depositary Shares in the third quarter worth about $279,000. Entropy Technologies LP acquired a new stake in Lakefront Biotherapeutics American Depositary Shares in the 3rd quarter valued at about $887,000. Marshall Wace LLP bought a new position in shares of Lakefront Biotherapeutics American Depositary Shares during the 3rd quarter valued at about $2,326,000. Finally, Alps Advisors Inc. bought a new position in shares of Lakefront Biotherapeutics American Depositary Shares during the 3rd quarter valued at about $2,617,000. 32.46% of the stock is owned by institutional investors.
About Lakefront Biotherapeutics American Depositary Shares
(
Get Free Report)
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Lakefront Biotherapeutics American Depositary Shares, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lakefront Biotherapeutics American Depositary Shares wasn't on the list.
While Lakefront Biotherapeutics American Depositary Shares currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.